The performance of the GALAD score to detect early-stage HCC remains controversial.[28], [29], [30] Other scores, such as the HCC risk score aMAP and the Toronto HCC risk index (THRI), were developed to discriminate between low- and high-risk patients.[31], [32], [33] The combination of clinical and genetic predictors, such as patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) single nucleotide polymorphisms (SNPs), may improve HCC risk stratification.34 The gene discussed is TM6SF2; the disease is hepatocellular carcinoma.